ENTERA BIO LTD. Deferred Federal, State and Local, Tax Expense (Benefit)
ENTERA BIO LTD. (ENTX) reported Deferred Federal, State and Local, Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2026-03-27
- ENTERA BIO LTD. deferred federal, state and local, tax expense (benefit) for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- ENTERA BIO LTD. deferred federal, state and local, tax expense (benefit) for fiscal 2024 was $14.00K, a 51.72% decline from fiscal 2023.
- ENTERA BIO LTD. deferred federal, state and local, tax expense (benefit) for fiscal 2023 was $29.00K, a 83.33% decline from fiscal 2022.
- ENTERA BIO LTD. deferred federal, state and local, tax expense (benefit) for fiscal 2022 was $174.00K.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-27 |
| 2024-12-31 | $14.00K 10-K · filed 2026-03-27 |
| 2023-12-31 | $29.00K 10-K · filed 2025-03-28 |
| 2022-12-31 | $174.00K 10-K · filed 2024-03-08 |
| 2021-12-31 | -$217.00K 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |